Genetic and Epigenetic Pathogenesis of Acromegaly

1. Hannah-Shmouni, F.; Trivellin, G.; Stratakis, C.A. Genetics of gigantism and acromegaly. Growth Horm. IGF Res. 2016, 30–31, 37–41. [CrossRef] [PubMed]

2. Ghazi, A.A.; Amirbaigloo, A.; Dezfooli, A.A.; Saadat, N.; Ghazi, S.; Pourafkari, M.; Tirgari, F.; Dhall, D.; Bannykh, S.; Melmed, S.; et al. Ectopic acromegaly due to growth hormone releasing hormone. Endocrine 2012, 43, 293–302. [CrossRef] [PubMed]

3. Asa, S.L.; Mete, O. Hypothalamic Endocrine Tumors: An Update. J. Clin. Med. 2019, 8, 1741. [CrossRef] [PubMed]

4. Asa, S.L.; Mete, O.; Perry, A.; Osamura, R.Y. Overview of the 2022 WHO Classification of Pituitary Tumors. Endocr. Pathol. 2022, 33, 6–26. [CrossRef]

5. Potorac, I.; Petrossians, P.; Daly, A.F.; Schillo, F.; Ben Slama, C.; Nagi, S.; Sahnoun, M.; Brue, T.; Girard, N.; Chanson, P.; et al. Pituitary MRI characteristics in 297 acromegaly patients based on T2-weighted sequences. Endocr.-Relat. Cancer 2015, 22, 169–177. [CrossRef]

6. Heck, A.; Ringstad, G.; Fougner, S.L.; Casar-Borota, O.; Nome, T.; Ramm-Pettersen, J.; Bollerslev, J. Intensity of pituitary adenoma on T2-weighted magnetic resonance imaging predicts the response to octreotide treatment in newly diagnosed acromegaly. Clin. Endocrinol. 2011, 77, 72–78. [CrossRef]

7. Matsumoto, R.; Izawa, M.; Fukuoka, H.; Iguchi, G.; Odake, Y.; Yoshida, K.; Bando, H.; Suda, K.; Nishizawa, H.; Takahashi, M.; et al. Genetic and clinical characteristics of Japanese patients with sporadic somatotropinoma. Endocr. J. 2016, 63, 953–963. [CrossRef]

8. Peculis, R.; Niedra, H.; Rovite, V. Large Scale Molecular Studies of Pituitary Neuroendocrine Tumors: Novel Markers, Mechanisms and Translational Perspectives. Cancers 2021, 13, 1395. [CrossRef]

9. Herman, V.; Fagin, J.; Gonsky, R.; Kovacs, K.; Melmed, S. Clonal origin of pituitary adenomas. J. Clin. Endocrinol. Metab. 1990, 71, 1427–1433. [CrossRef]

10. Vasilev, V.; Daly, A.F.; Zacharieva, S.; Beckers, A. Clinical and Molecular Update on Genetic Causes of Pituitary Adenomas. Horm. Metab. Res. 2020, 52, 553–561. [CrossRef]

11. Srirangam Nadhamuni, V.; Korbonits, M. Novel Insights into Pituitary Tumorigenesis: Genetic and Epigenetic Mechanisms. Endocr. Rev. 2020, 41, 821–846. [CrossRef] [PubMed]

12. Ye, Z.; Li, Z.; Wang, Y.; Mao, Y.; Shen, M.; Zhang, Q.; Li, S.; Zhou, L.; Shou, X.; Chen, J.; et al. Common variants at 10p12.31, 10q21.1 and 13q12.13 are associated with sporadic pituitary adenoma. Nat. Genet. 2015, 47, 793–797. [CrossRef] [PubMed]

13. Salomon, M.P.; Wang, X.; Marzese, D.M.; Hsu, S.C.; Nelson, N.; Zhang, X.; Matsuba, C.; Takasumi, Y.; Ballesteros-Merino, C.; Fox, B.A.; et al. The Epigenomic Landscape of Pituitary Adenomas Reveals Specific Alterations and Differentiates Among Acromegaly, Cushing’s Disease and Endocrine-Inactive Subtypes. Clin. Cancer Res. 2018, 24, 4126–4136. [CrossRef] [PubMed]

14. Bi, W.L.; Horowitz, P.; Greenwald, N.F.; Abedalthagafi, M.; Agarwalla, P.K.; Gibson, W.J.; Mei, Y.; Schumacher, S.E.; Ben-David, U.; Chevalier, A.; et al. Landscape of Genomic Alterations in Pituitary Adenomas. Clin. Cancer Res. 2017, 23, 1841–1851. [CrossRef]

15. Ben-Shlomo, A.; Deng, N.; Ding, E.; Yamamoto, M.; Mamelak, A.; Chesnokova, V.; Labadzhyan, A.; Melmed, S. DNA damage and growth hormone hypersecretion in pituitary somatotroph adenomas. J. Clin. Investig. 2020, 130, 5738–5755. [CrossRef]

16. Reincke, M.; Sbiera, S.; Hayakawa, A.; Theodoropoulou, M.; Osswald, A.; Beuschlein, F.; Meitinger, T.; Mizuno-Yamasaki, E.; Kawaguchi, K.; Saeki, Y.; et al. Mutations in the deubiquitinase gene USP8 cause Cushing’s disease. Nat. Genet. 2014, 47, 31–38. [CrossRef]

17. Song, Z.-J.; Reitman, Z.; Ma, Z.-Y.; Chen, J.-H.; Zhang, Q.-L.; Shou, X.-F.; Huang, C.-X.; Wang, Y.-F.; Li, S.-Q.; Mao, Y.; et al. The genome-wide mutational landscape of pituitary adenomas. Cell Res. 2016, 26, 1255–1259. [CrossRef]

18. Välimäki, N.; Schalin-Jäntti, C.; Karppinen, A.; Paetau, A.; Kivipelto, L.; Aaltonen, L.A.; Karhu, A. Genetic and Epigenetic Characterization of Growth Hormone–Secreting Pituitary Tumors. Mol. Cancer Res. 2019, 17, 2432–2443. [CrossRef]

19. Landis, C.A.; Masters, S.B.; Spada, A.; Pace, A.M.; Bourne, H.R.; Vallar, L. GTPase inhibiting mutations activate the α chain of Gs and stimulate adenylyl cyclase in human pituitary tumours. Nature 1989, 340, 692–696. [CrossRef]

20. Weinstein, L.S.; Liu, J.; Sakamoto, A.; Xie, T.; Chen, M. Minireview: GNAS: Normal and abnormal functions. Endocrinology 2004, 145, 5459–5464. [CrossRef]

21. Hosoi, E.; Yokogoshi, Y.; Hosoi, E.; Horie, H.; Sano, T.; Yamada, S.; Saito, S. Analysis of the Gs α gene in growth hormone- secreting pituitary adenomas by the polymerase chain reaction-direct sequencing method using paraffin-embedded tissues. Eur. J. Endocrinol. 1993, 129, 301–306. [CrossRef] [PubMed]

22. Kim, H.J.; Kim, M.S.; Park, Y.J.; Kim, S.W.; Park, D.J.; Park, K.S.; Kim, S.Y.; Cho, B.Y.; Lee, H.K.; Jung, H.W.; et al. Prevalence of Gs alpha mutations in Korean patients with pituitary adenomas. J. Endocrinol. 2001, 168, 221–226. [CrossRef]

23. Spada, A.; Arosio, M.; Bochicchio, D.; Bazzoni, N.; Vallar, L.; Bassetti, M.; Faglia, G. Clinical, Biochemical, and Morphological Correlates in Patients Bearing Growth Hormone-Secreting Pituitary Tumors with or without Constitutively Active Adenylyl Cyclase. J. Clin. Endocrinol. Metab. 1990, 71, 1421–1426. [CrossRef] [PubMed]

24. Barlier, A.; Gunz, G.; Zamora, A.J.; Morange-Ramos, I.; Figarella-Branger, D.; Dufour, H.; Enjalbert, A.; Jaquet, P. Pronostic and therapeutic consequences of Gs alpha mutations in somatotroph adenomas. J. Clin. Endocrinol. Metab. 1998, 83, 1604–1610. [PubMed]

25. Yoshimoto, K.; Iwahana, H.; Fukuda, A.; Sano, T.; Itakura, M. Rare mutations of the Gs alpha subunit gene in human endocrine tumors. Mutation detection by polymerase chain reaction-primer-introduced restriction analysis. Cancer 1993, 72, 1386–1393. [CrossRef]

26. Yasufuku-Takano, J.; Takano, K.; Morita, K.; Takakura, K.; Teramoto, A.; Fujita, T. Does the prevalence of gsp mutations in GH-secreting pituitary adenomas differ geographically or racially? Prevalence of gsp mutations in Japanese patients revisited. Clin. Endocrinol. 2005, 64, 91–96. [CrossRef] [PubMed]

27. Ronchi, C.L.; Peverelli, E.; Herterich, S.; Weigand, I.; Mantovani, G.; Schwarzmayr, T.; Sbiera, S.; Allolio, B.; Honegger, J.; Appenzeller, S.; et al. Landscape of somatic mutations in sporadic GH-secreting pituitary adenomas. Eur. J. Endocrinol. 2016, 174, 363–372. [CrossRef]

28. Välimäki, N.; Demir, H.; Pitkänen, E.; Kaasinen, E.; Karppinen, A.; Kivipelto, L.; Schalin-Jäntti, C.; Aaltonen, L.A.; Karhu, A. Whole-Genome Sequencing of Growth Hormone (GH)-Secreting Pituitary Adenomas. J. Clin. Endocrinol. Metab. 2015, 100, 3918–3927. [CrossRef]

29. Puig-Domingo, M.; Gil, J.; Sampedro-Nuñez, M.; Jordà, M.; Webb, S.M.; Serra, G.; Pons, L.; Salinas, I.; Blanco, A.; Marques-Pamies, M.; et al. Molecular profiling for acromegaly treatment: A validation study. Endocr.-Relat. Cancer 2020, 27, 375–389. [CrossRef]

30. Creo, A.L.; Lteif, A.N. Pituitary gigantism: A retrospective case series. J. Pediatr. Endocrinol. Metab. 2016, 29, 597–602. [CrossRef]

31. Watanabe, D.; Yagasaki, H.; Kojika, S.; Ogiwara, M.; Kinouchi, H.; Nakane, T.; Inukai, T. GH/PRL-secreting pituitary macroade- noma associated with GNAS p.Gln227Leu mutation: Pediatric case report and review. Endocr. J. 2019, 66, 403–408. [CrossRef] [PubMed]

32. Larkin, S.; Reddy, R.; Karavitaki, N.; Cudlip, S.; Wass, J.; Ansorge, O. Granulation pattern, but not GSP or GHR mutation, is associated with clinical characteristics in somatostatin-naive patients with somatotroph adenomas. Eur. J. Endocrinol. 2013, 168, 491–499. [CrossRef] [PubMed]

33. Agarwal, S.; Kester, M.B.; Debelenko, L.V.; Heppner, C.; Emmert-Buck, M.R.; Skarulis, M.C.; Doppman, J.L.; Kim, Y.S.; Lubensky, I.A.; Zhuang, Z.; et al. Germline mutations of the MEN1 gene in familial multiple endocrine neoplasia type 1 and related states. Hum. Mol. Genet. 1997, 6, 1169–1175. [CrossRef] [PubMed]

34. Lemos, M.C.; Thakker, R.V. Multiple endocrine neoplasia type 1 (MEN1): Analysis of 1336 mutations reported in the first decade following identification of the gene. Hum. Mutat. 2008, 29, 22–32. [CrossRef]

35. Thakker, R.V.; Newey, P.J.; Walls, G.V.; Bilezikian, J.; Dralle, H.; Ebeling, P.R.; Melmed, S.; Sakurai, A.; Tonelli, F.; Brandi, M.L. Clinical Practice Guidelines for Multiple Endocrine Neoplasia Type 1 (MEN1). J. Clin. Endocrinol. Metab. 2012, 97, 2990–3011. [CrossRef]

36. Sakurai, A.; Suzuki, S.; Kosugi, S.; Okamoto, T.; Uchino, S.; Miya, A.; Imai, T.; Kaji, H.; Komoto, I.; Miura, D.; et al. Multiple endocrine neoplasia type 1 in Japan: Establishment and analysis of a multicentre database. Clin. Endocrinol. 2011, 76, 533–539. [CrossRef]

37. Cuny, T.; Pertuit, M.; Sahnoun-Fathallah, M.; Daly, A.; Occhi, G.; Odou, M.F.; Tabarin, A.; Nunes, M.L.; Delemer, B.; Rohmer, V.; et al. Genetic analysis in young patients with sporadic pituitary macroadenomas: Besides AIP don’t forget MEN1 genetic analysis. Eur. J. Endocrinol. 2013, 168, 533–541. [CrossRef]

38. Milne, T.A.; Hughes, C.M.; Lloyd, R.; Yang, Z.; Rozenblatt-Rosen, O.; Dou, Y.; Schnepp, R.W.; Krankel, C.; LiVolsi, V.A.; Gibbs, D.; et al. Menin and MLL cooperatively regulate expression of cyclin-dependent kinase inhibitors. Proc. Natl. Acad. Sci. USA 2005, 102, 749–754. [CrossRef]

39. Karnik, S.K.; Hughes, C.M.; Gu, X.; Rozenblatt-Rosen, O.; McLean, G.W.; Xiong, Y.; Meyerson, M.; Kim, S.K. Menin regulates pancreatic islet growth by promoting histone methylation and expression of genes encoding p27Kip1 and p18INK4c. Proc. Natl. Acad. Sci. USA 2005, 102, 14659–14664. [CrossRef]

40. Chasseloup, F.; Pankratz, N.; Lane, J.; Faucz, F.R.; Keil, M.F.; Chittiboina, P.; Kay, D.M.; Tayeb, T.H.; A Stratakis, C.; Mills, J.L.; et al. Germline CDKN1B Loss-of-Function Variants Cause Pediatric Cushing’s Disease with or without an MEN4 Phenotype. J. Clin. Endocrinol. Metab. 2020, 105, 1983–2005. [CrossRef]

41. Frederiksen, A.L.; Rossing, M.; Hermann, P.; Ejersted, C.; Thakker, R.V.; Frost, M. Clinical Features of Multiple Endocrine Neoplasia Type 4: Novel Pathogenic Variant and Review of Published Cases. J. Clin. Endocrinol. Metab. 2019, 104, 3637–3646. [CrossRef] [PubMed]

42. Boguslawska, A.; Korbonits, M. Genetics of Acromegaly and Gigantism. J. Clin. Med. 2021, 10, 1377. [CrossRef] [PubMed]

43. Forlino, A.; Vetro, A.; Garavelli, L.; Ciccone, R.; London, E.; Stratakis, C.A.; Zuffardi, A. PRKACB and Carney complex. N. Engl. J. Med. 2014, 370, 1065–1067. [CrossRef] [PubMed]

44. Espiard, S.; Vantyghem, M.-C.; Assié, G.; Cardot-Bauters, C.; Raverot, G.; Brucker-Davis, F.; Archambeaud-Mouveroux, F.; Lefebvre, H.; Nunes, M.-L.; Tabarin, A.; et al. Frequency and Incidence of Carney Complex Manifestations: A Prospective Multicenter Study with a Three-Year Follow-Up. J. Clin. Endocrinol. Metab. 2020, 105, e436–e446. [CrossRef]

45. Cuny, T.; Mac, T.T.; Romanet, P.; Dufour, H.; Morange, I.; Albarel, F.; Lagarde, A.; Castinetti, F.; Graillon, G.T.; North, M.O.; et al. Acromegaly in Carney complex. Pituitary 2019, 22, 456–466. [CrossRef]

46. Dumitrescu, C.E.; Collins, M.T. McCune-Albright syndrome. Orphanet J. Rare Dis. 2008, 3, 12. [CrossRef]

47. Rostomyan, L.; Daly, A.; Petrossians, P.; Nachev, E.; Lila, A.R.; Lecoq, A.-L.; Lecumberri, B.; Trivellin, G.; Salvatori, R.; Moraitis, A.G.; et al. Clinical and genetic characterization of pituitary gigantism: An international collaborative study in 208 patients. Endocr.-Relat. Cancer 2015, 22, 745–757. [CrossRef]

48. Javaid, M.K.; Boyce, A.; Appelman-Dijkstra, N.; Ong, J.; Defabianis, P.; Offiah, A.; Arundel, P.; Shaw, N.; Dal Pos, V.; Underhil, A.; et al. Best practice management guidelines for fibrous dysplasia/McCune-Albright syndrome: A consensus statement from the FD/MAS international consortium. Orphanet J. Rare Dis. 2019, 14, 139. [CrossRef]

49. Salenave, S.; Boyce, A.M.; Collins, M.T.; Chanson, P. Acromegaly and McCune-Albright syndrome. J. Clin. Endocrinol. Metab. 2014, 99, 1955–1969. [CrossRef]

50. Boyce, A.M.; Brewer, C.; DeKlotz, T.R.; Zalewski, C.K.; King, K.A.; Collins, M.T.; Kim, H.J. Association of Hearing Loss and Otologic Outcomes with Fibrous Dysplasia. JAMA Otolaryngol. Neck Surg. 2018, 144, 102–107. [CrossRef]

51. Boyce, A.M.; Glover, M.; Kelly, M.H.; Brillante, B.A.; Butman, J.A.; Fitzgibbon, E.J.; Brewer, C.C.; Zalewski, C.K.; Cutler Peck, C.M.; Jeffrey Kim, H.; et al. Optic neuropathy in McCune-Albright syndrome: Effects of early diagnosis and treatment of growth hormone excess. J. Clin. Endocrinol. Metab. 2013, 98, E126–E134. [CrossRef] [PubMed]

52. Romanet, P.; Philibert, P.; Fina, F.; Cuny, T.; Roche, C.; Ouafik, L.; Paris, F.; Reynaud, R.; Barlier, A. Using Digital Droplet Polymerase Chain Reaction to Detect the Mosaic GNAS Mutations in Whole Blood DNA or Circulating Cell-Free DNA in Fibrous Dysplasia and McCune-Albright Syndrome. J. Pediatr. 2019, 205, 281–285.e4. [CrossRef] [PubMed]

53. Beckers, A.; Aaltonen, L.A.; Daly, A.F.; Karhu, A. Familial isolated pituitary adenomas (FIPA) and the pituitary adenoma predisposition due to mutations in the aryl hydrocarbon receptor interacting protein (AIP) gene. Endocr. Rev. 2013, 34, 239–277. [CrossRef] [PubMed]

54. Daly, A.F.; Beckers, A. Familial isolated pituitary adenomas (FIPA) and mutations in the aryl hydrocarbon receptor interacting protein (AIP) gene. Endocrinol. Metab. Clin. N. Am. 2015, 44, 19–25. [CrossRef]

55. Daly, A.F.; Jaffrain-Rea, M.-L.; Ciccarelli, A.; Valdes-Socin, H.; Rohmer, V.; Tamburrano, G.; Borson-Chazot, C.; Estour, B.; Brue, T.; Ferolla, P.; et al. Clinical Characterization of Familial Isolated Pituitary Adenomas. J. Clin. Endocrinol. Metab. 2006, 91, 3316–3323. [CrossRef] [PubMed]

56. Daly, A.F.; Trivellin, G.; Stratakis, C.A. Gigantism, acromegaly, and GPR101 mutations. N. Engl. J. Med. 2015, 372, 1265. [PubMed]

57. Vierimaa, O.; Georgitsi, M.; Lehtonen, R.; Vahteristo, P.; Kokko, A.; Raitila, A.; Tuppurainen, K.; Ebeling, T.M.L.; Salmela, P.I.; Paschke, R.; et al. Pituitary Adenoma Predisposition Caused by Germline Mutations in the AIP Gene. Science 2006, 312, 1228–1230. [CrossRef] [PubMed]

58. Marques, P.; Caimari, F.; Hernandez-Ramirez, L.C.; Collier, D.; Iacovazzo, D.; Ronaldson, A.; Magid, K.; Lim, C.T.; Stals, K.; Ellard, S.; et al. Significant Benefits of AIP Testing and Clinical Screening in Familial Isolated and Young-onset Pituitary Tumors. J. Clin. Endocrinol. Metab. 2020, 105, e2247–e2260. [CrossRef]

59. Lecoq, A.L.; Kamenicky, P.; Guiochon-Mantel, A.; Chanson, P. Genetic mutations in sporadic pituitary adenomas–what to screen for? Nat. Rev. Endocrinol. 2015, 11, 43–54. [CrossRef]

60. Trivellin, G.; Korbonits, M. AIP and its interacting partners. J. Endocrinol. 2011, 210, 137–155. [CrossRef]

61. Trivellin, G.; Daly, A.F.; Faucz, F.R.; Yuan, B.; Rostomyan, L.; Larco, D.O.; Schernthaner-Reiter, M.H.; Szarek, E.; Leal, L.F.; Caberg, J.-H.; et al. Gigantism and Acromegaly Due to Xq26 Microduplications and GPR101 Mutation. N. Engl. J. Med. 2014, 371, 2363–2374. [CrossRef] [PubMed]

62. Abboud, D.; Daly, A.F.; Dupuis, N.; Bahri, M.A.; Inoue, A.; Chevigné, A.; Ectors, F.; Plenevaux, A.; Pirotte, B.; Beckers, A.; et al. GPR101 drives growth hormone hypersecretion and gigantism in mice via constitutive activation of Gs and Gq/11. Nat. Commun. 2020, 11, 1–16. [CrossRef] [PubMed]

63. Beckers, A.; Lodish, M.B.; Trivellin, G.; Rostomyan, L.; Lee, M.; Faucz, F.R.; Yuan, B.; Choong, C.S.; Caberg, J.-H.; Verrua, E.; et al. X-linked acrogigantism syndrome: Clinical profile and therapeutic responses. Endocr.-Relat. Cancer 2015, 22, 353–367. [CrossRef] [PubMed]

64. Iacovazzo, D.; Caswell, R.; Bunce, B.; Jose, S.; Yuan, B.; Hernández-Ramírez, L.C.; Kapur, S.; Caimari, F.; Evanson, J.; Ferraù, F.; et al. Germline or somatic GPR101 duplication leads to X-linked acrogigantism: A clinico-pathological and ge- netic study. Acta Neuropathol. Commun. 2016, 4, 4752. [CrossRef]

65. Naves, L.A.; Daly, A.; Dias, L.A.; Yuan, B.; Zakir, J.C.O.; Barra, G.; Palmeira, L.; Villa, C.; Trivellin, G.; Júnior, A.J.; et al. Aggressive tumor growth and clinical evolution in a patient with X-linked acro-gigantism syndrome. Endocrine 2015, 51, 236–244. [CrossRef] [PubMed]

66. Xekouki, P.; Brennand, A.; Whitelaw, B.; Pacak, K.; Stratakis, C.A. The 3PAs: An Update on the Association of Pheochromocytomas, Paragangliomas, and Pituitary Tumors. Horm. Metab. Res. 2019, 51, 419–436. [CrossRef]

67. Daly, A.F.; Castermans, E.; Oudijk, L.; A Guitelman, M.; Beckers, P.; Potorac, I.; Neggers, S.J.C.M.M.; Sacre, N.; van der Lely, A.-J.; Bours, V.; et al. Pheochromocytomas and pituitary adenomas in three patients with MAX exon deletions. Endocr.-Relat. Cancer 2018, 25, L37–L42. [CrossRef]

68. Hannah-Shmouni, F.; Trivellin, G.; Beckers, P.; Karaviti, L.P.; Lodish, M.; Tatsi, C.; Adesina, A.M.; Adamidou, F.; Mintziori, G.; Josefson, J.L.; et al. Neurofibromatosis Type 1 Has a Wide Spectrum of Growth Hormone Excess. J. Clin. Med. 2022, 11, 2168. [CrossRef]

69. Hozumi, K.; Fukuoka, H.; Odake, Y.; Takeuchi, T.; Uehara, T.; Sato, T.; Inoshita, N.; Yoshida, K.; Matsumoto, R.; Bando, H.; et al. Acromegaly caused by a somatotroph adenoma in patient with neurofibromatosis type 1. Endocr. J. 2019, 66, 853–857. [CrossRef]

70. Hoffman, W.H.; Perrin, J.C.; Halac, E.; Gala, R.R.; England, B.G. Acromegalic gigantism and tuberous sclerosis. J. Pediatr. 1978, 93, 478–480. [CrossRef]

71. Melmed, S.; Kaiser, U.B.; Lopes, M.B.; Bertherat, J.; Syro, L.V.; Raverot, G.; Reincke, M.; Johannsson, G.; Beckers, A.; Fleseriu, M.; et al. Clinical Biology of the Pituitary Adenoma. Endocr. Rev. 2022, bnac010. [CrossRef] [PubMed]

72. Vlotides, G.; Eigler, T.; Melmed, S. Pituitary tumor-transforming gene: Physiology and implications for tumorigenesis. Endocr. Rev. 2007, 28, 165–186. [CrossRef] [PubMed]

73. Trautmann, K.; Thakker, R.; Ellison, D.; Ibrahim, A.; Lees, P.; Harding, B.; Fischer, C.; Popp, S.; Bartram, C.; Jauch, A. Chromosomal aberrations in sporadic pituitary tumors. Int. J. Cancer 2001, 91, 809–814. [CrossRef]

74. Neou, M.; Villa, C.; Armignacco, R.; Jouinot, A.; Raffin-Sanson, M.-L.; Septier, A.; Letourneur, F.; Diry, S.; Diedisheim, M.; Izac, B.; et al. Pangenomic Classification of Pituitary Neuroendocrine Tumors. Cancer Cell 2019, 37, 123–134.e5. [CrossRef]

75. Fagin, J.A.; Petrini, J.H. Oncogene-induced DNA damage: Cyclic AMP steps into the ring. J. Clin. Investig. 2020, 130, 5668–5670. [CrossRef]

76. Ling, C.; Pease, M.; Shi, L.; Punj, V.; Shiroishi, M.S.; Commins, D.; Weisenberger, D.J.; Wang, K.; Zada, G. A Pilot Genome-Scale Profiling of DNA Methylation in Sporadic Pituitary Macroadenomas: Association with Tumor Invasion and Histopathological Subtype. PLoS ONE 2014, 9, e96178. [CrossRef]

77. Ashton, C.; Rhie, S.K.; Carmichael, J.D.; Zada, G. Role of KCNAB2 expression in modulating hormone secretion in somatotroph pituitary adenoma. J. Neurosurg. 2020, 134, 787–793. [CrossRef]

78. Ma, C.; Liu, Y.; He, L. MicroRNAs-powerful repression comes from small RNAs. Sci. China C Life Sci. 2009, 52, 323–330. [CrossRef]

79. Bottoni, A.; Piccin, D.; Tagliati, F.; Luchin, A.; Zatelli, M.C.; degli Uberti, E. miR-15a and miR-16-1 down-regulation in pituitary adenomas. J. Cell. Physiol. 2005, 204, 280–285. [CrossRef]

80. Elzein, S.; Goodyer, C.G. Regulation of human growth hormone receptor expression by microRNAs. Mol. Endocrinol. 2014, 28, 1448–1459. [CrossRef]

81. D’Angelo, D.; Palmieri, D.; Mussnich, P.; Roche, M.; Wierinckx, A.; Raverot, G.; Fedele, M.; Croce, C.M.; Trouillas, J.; Fusco, A. Altered MicroRNA Expression Profile in Human Pituitary GH Adenomas: Down-Regulation of miRNA Targeting HMGA1, HMGA2, and E2F1. J. Clin. Endocrinol. Metab. 2012, 97, E1128–E1138. [CrossRef] [PubMed]

82. Palumbo, T.; Faucz, F.R.; Azevedo, M.; Xekouki, P.; Iliopoulos, D.; A Stratakis, C. Functional screen analysis reveals miR-26b and miR-128 as central regulators of pituitary somatomammotrophic tumor growth through activation of the PTEN–AKT pathway. Oncogene 2012, 32, 1651–1659. [CrossRef] [PubMed]

83. Leone, V.; Langella, C.; D’Angelo, D.; Mussnich, P.; Wierinckx, A.; Terracciano, L.; Raverot, G.; Lachuer, J.; Rotondi, S.; Jaffrain-Rea, M.-L.; et al. miR-23b and miR-130b expression is downregulated in pituitary adenomas. Mol. Cell. Endocrinol. 2014, 390, 1–7. [CrossRef]

84. Fan, X.; Mao, Z.; He, D.; Liao, C.; Jiang, X.; Lei, N.; Hu, B.; Wang, X.; Li, Z.; Lin, Y.; et al. Expression of somatostatin receptor subtype 2 in growth hormone-secreting pituitary adenoma and the regulation of miR-185. J. Endocrinol. Investig. 2015, 38, 1117–1128. [CrossRef]

85. Lee, Y.J.; Cho, J.M.; Moon, J.H.; Ku, C.R.; Kim, J.; Kim, S.H.; Lee, E.J. Increased miR-338-3p expression correlates with invasiveness of GH-producing pituitary adenomas. Endocrine 2017, 58, 184–189. [CrossRef] [PubMed]

86. Zhao, S.; Li, J.; Feng, J.; Li, Z.; Liu, Q.; Lv, P.; Wang, F.; Gao, H.; Zhang, Y. Identification of Serum miRNA-423-5p Expression Signature in Somatotroph Adenomas. Int. J. Endocrinol. 2019, 2019, 1–12. [CrossRef] [PubMed]

87. Trivellin, G.; Butz, H.; Delhove, J.; Igreja, S.; Chahal, H.S.; Zivkovic, V.; McKay, T.; Patócs, A.; Grossman, A.B.; Korbonits, M. MicroRNA miR-107 is overexpressed in pituitary adenomas and inhibits the expression of aryl hydrocarbon receptor-interacting protein in vitro. Am. J. Physiol. Endocrinol. Metab. 2012, 303, E708–E719. [CrossRef]

88. He, Z.; Chen, L.; Hu, X.; Tang, J.; He, L.; Hu, J.; Fei, F.; Wang, Q. Next-generation sequencing of microRNAs reveals a unique expression pattern in different types of pituitary adenomas. Endocr. J. 2019, 66, 709–722. [CrossRef]

89. Xiong, Y.; Tang, Y.; Fan, F.; Zeng, Y.; Li, C.; Zhou, C.; Hu, Z.; Zhang, L.; Liu, Z. Exosomal hsa-miR-21-5p derived from growth hormone-secreting pituitary adenoma promotes abnormal bone formation in acromegaly. Transl. Res. 2020, 215, 1–16. [CrossRef]

90. Mercer, T.R.; Dinger, M.E.; Mattick, J.S. Long non-coding RNAs: Insights into functions. Nat. Rev. Genet. 2009, 10, 155–159. [CrossRef]

91. Wu, Z.R.; Yan, L.; Liu, Y.T.; Cao, L.; Guo, Y.H.; Zhang, Y.; Yao, H.; Cai, L.; Shang, H.B.; Rui, W.W.; et al. Inhibition of mTORC1 by lncRNA H19 via disrupting 4E-BP1/Raptor interaction in pituitary tumours. Nat. Commun. 2018, 9, 4624. [CrossRef] [PubMed]

92. Lu, T.; Yu, C.; Ni, H.; Liang, W.; Yan, H.; Jin, W. Expression of the long non-coding RNA H19 and MALAT-1 in growth hormone-secreting pituitary adenomas and its relationship to tumor behavior. Int. J. Dev. Neurosci. 2018, 67, 46–50. [CrossRef] [PubMed]

93. Zhang, X.; Zhou, Y.; Mehta, K.R.; Danila, D.C.; Scolavino, S.; Johnson, S.R.; Klibanski, A. A Pituitary-Derived MEG3 Isoform Functions as a Growth Suppressor in Tumor Cells. J. Clin. Endocrinol. Metab. 2003, 88, 5119–5126. [CrossRef]

94. Mezzomo, L.C.; Gonzales, P.H.; Pesce, F.G.; Kretzmann Filho, N.; Ferreira, N.P.; Oliveira, M.C.; Kohek, M.B.F. Expression of cell growth negative regulators MEG3 and GADD45gamma is lost in most sporadic human pituitary adenomas. Pituitary 2012, 15, 420–427. [CrossRef]

95. Tang, C.; Zhong, C.; Cong, Z.; Yang, J.; Wen, G.; Zhu, J.; Ma, C. MEG3 is associated with gsp oncogene regulation of growth hormone hypersecretion, proliferation and invasiveness of human GH-secreting adenomas. Oncol. Lett. 2019, 17, 3495–3502. [CrossRef] [PubMed]